Philip M Neal Net Worth

The estimated Net Worth of Philip M Neal is at least 16.4 百万$ dollars as of 14 November 2005. Philip Neal owns over 50,000 units of Edwards Lifesciences Corp stock worth over 16,395,493$ and over the last 22 years Philip sold EW stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Philip Neal EW stock SEC Form 4 insiders trading

Philip has made over 2 trades of the Edwards Lifesciences Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently Philip exercised 50,000 units of EW stock worth 1,181,500$ on 14 November 2005.

The largest trade Philip's ever made was exercising 82,000 units of Edwards Lifesciences Corp stock on 17 November 2004 worth over 1,332,500$. On average, Philip trades about 7,333 units every 20 days since 2003. As of 14 November 2005 Philip still owns at least 240,227 units of Edwards Lifesciences Corp stock.

You can see the complete history of Philip Neal stock trades at the bottom of the page.

What's Philip Neal's mailing address?

Philip's mailing address filed with the SEC is , , , , .

Insiders trading at Edwards Lifesciences Corp

Over the last 22 years, insiders at Edwards Lifesciences Corp have traded over 94,964,396$ worth of Edwards Lifesciences Corp stock and bought 47,398 units worth 3,992,090$ . The most active insiders traders include Michael A Mussallem、Donald E Jr Bobo、Steven R Loranger. On average, Edwards Lifesciences Corp executives and independent directors trade stock every 8 days with the average trade being worth of 1,126,057$. The most recent stock trade was executed by Donald E Jr Bobo on 11 September 2024, trading 5,000 units of EW stock currently worth 226,400$.

What does Edwards Lifesciences Corp do?

edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.

Complete history of Philip Neal stock trades at Avery Dennison、Edwards Lifesciences Corp

Edwards Lifesciences Corp executives and stock owners

Edwards Lifesciences Corp executives and other stock owners filed with the SEC include:

• Michael Mussallem,
  Chairman of the Board, Chief Executive Officer
• Scott Ullem,
  Chief Financial Officer, Corporate Vice President
• Larry Wood,
  Corporate Vice President - Transcatheter Aortic Valve Replacement
• Donald Bobo,
  Corporate Vice President - Strategy and Corporate Development
• Catherine Szyman,
  Corporate Vice President - Critical Care
• Jean-Luc Lemercier,
  Corporate Vice President - EMEA (Europe, Middle East and Africa)
• Michael A. Mussallem,
  Chairman & CEO
• Jean-Luc Lemercier,
  Corp. VP of Europe, Middle East, Africa, Canada & Latin America
• Scott B. Ullem,
  Corp. VP & CFO
• Larry L. Wood,
  Corp. VP of Transcatheter Aortic Valve Replacement
• Donald E. Bobo Jr.,
  Corp. VP of Strategy & Corp. Devel.
• Heisz Stone,
  Independent Director
• William Link,
  Independent Director
• Kieran Gallahue,
  Independent Director
• Steven Loranger,
  Independent Director
• Nicholas Valeriani,
  Independent Director
• Martha Marsh,
  Lead Independent Director
• Paul LaViolette,
  Director
• Ramona Sequeira,
  Director
• Daveen Chopra,
  Corporate Vice President - Surgical Structural Heart
• Huimin Wang,
  Corporate Vice President - Japan, Asia and Pacific
• Christine Z. McCauley,
  Corp. VP of HR
• Dirksen J. Lehman,
  Corp. VP of Public Affairs
• Arnold A. Pinkston,
  Corp. VP & Gen. Counsel
• Mark Wilterding,
  VP of Investor Relations
• Dr. Todd J. Brinton,
  Corp. VP of Advanced Technology & Chief Scientific Officer
• Patrick B Verguet,
  CVP, Europe
• John T Cardis,
  Director
• Schack Wesley W Von,
  Director
• Daniel J. Lippis,
  CVP, JAPAC
• Carlyn D Solomon,
  CVP, Critical Care & Vascular
• David E I Pyott,
  Director
• Michael R Bowlin,
  Director
• Bruce P Garren,
  Corp VP, Gen Counsel & Secty
• Barbara J Mcneil,
  Director
• Robert Alexander Ingram,
  Director
• John H Jr Kehl,
  Corp VP, Strategy & Bus Dev
• Thomas M Abate,
  CVP, CFO and Treasurer
• Christine Z Mc Cauley,
  CVP, Human Resources
• Robert C Reindl,
  Corp VP, Human Resources
• Aimee S Weisner,
  CVP, General Counsel
• Vernon R Jr Loucks,
  Director
• Paul C Redmond,
  CVP, CardioVations Surgcl Sys
• Corinne H Nevinny,
  CVP, Chief Financial Officer
• Philip M Neal,
  Director
• Stuart L Foster,
  Corp VP, Technology/Discovery
• John Alexander Martin,
  CVP, North America
• Anita Bessler,
  Corp VP, Global Franchise Mgmt
• Randel William Woodgrift,
  Corp VP, Manufacturing Ops
• J Randall Nelson,
  Corp VP, North America
• David T Feinberg,
  Director
• Robert W.A. Sellers,
  SVP, Corporate Controller
• Bernard J Zovighian,
  CEO
• Wayne Markowitz,
  GM & SVP, Surgical
• Leslie C. Davis,
  Director